Abstract:Guided by molecular docking, a commonly used open-chain linker was cyclized into a five-membered pyrrolidine to lock the overall conformation of the propeller-shaped molecule. Different substituents were introduced into the pyrrolidine moiety to block oxidative metabolism. Surprisingly, it was found that a small methyl substituent could be used to alleviate the oxidative metabolism of pyrrolidine while maintaining or enhancing potency, which could be described as a "magic methyl". Further optimization around the "3rd blade" of the propeller led to identification of a series of potent and selective PI3Kδ inhibitors. Among them, compound 50 afforded an optimum balance of PK profiles and potency. Oral administration of 50 attenuated the arthritis severity in a dose-dependent manner in a collagen-induced arthritis model without obvious toxicity. Furthermore, 50 demonstrated excellent pharmacokinetic properties with high bioavailability, suggesting that 50 might be an acceptable candidate for treatment of inflammatory diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00004?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00004</a>.Binding affinities of 50 with 164 kinases (Table S1); predicted results of compound 43 from the CYP3A4, CYP2D6, and CYP2C9 models, respectively, in SMARTCyp (Tables S2–S4); effects of compound 50 and idelalisib on normal cell viability (Table S5); binding free energy (ΔGbindcal) for idelalisib/PI3Kδ complexes (Table S6); binding free energy (ΔGbindcal) for compound 50/PI3Kδ complexes (Table S7); cocrystal structure of 1 in PI3Kδ (Figure S1); docking model of compound 29 in PI3Kδ (Figure S2); pre-experiments of selected compounds and dexamethasone in collagen-induced arthritis models (Figure S3); snapshots of the idelalisib/PI3Kδ complex along the dynamic simulation time for 100th, 200th, 300th, 400th, and 500th ns (Figure S4); snapshots of the compound 50/PI3Kδ complex along the dynamic simulation time at 100th, 200th, 300th, 400th, and 500th ns (Figure S5); therapeutic efficacy of 50 in mice-established collagen-induced arthritis (Figure S6); HPLC spectra of compound 50 (Figure S6); 1H NMR spectra of compounds 26, 30, 45, 46, 47, 49, and 50 (Figures S8, S9, S10, S11, S12, S13, and S14, respectively); and biological assay methods: (1) kinase profile assay and IC50 test; (2) class I PI3K isoform-selective cellular assays (SKOV-3, 786-O, RAW 264.7, and RAJI cell lines); (3) basophil activation assay in HWB; (4) B cell activation assay in HWB; (5) primary human T-cell proliferation assays; (6) microsome stability assay; (7) pharmacokinetic study; (8) collagen-induced arthritis (CIA) model and treatment; and (9) histological examination (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_003.csv">CSV</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4XE0">4XE0</a> was used for docking in PI3Kδ of compounds 10, 29, 43, and 50 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00004/suppl_file/jm1c00004_si_002.zip">ZIP</a>)This article has not yet been cited by other publications.

Discovery of N -((3 S ,4 S )-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1 H -pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity

Discovery of N-((3S,4S)-4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl-1H-pyrazol-5-yl)benzamide (hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity.

Safety and Toxicology Study of Hu7691, a Novel AKT Inhibitor, Following Oral Administration in Rats

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Design, Synthesis and Biological Evaluation of Novel (Quinolinyl-3-pyridinyl)benzenesulfonamide-based Hydroxamic Acids As PI3K and HDAC Dual Targeting Inhibitors

Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel Benzopyran and Phenylpyrazole Derivatives as Akt Inhibitors.

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

Discovery of Pyrazole-Thiophene Derivatives As Highly Potent, Orally Active Akt Inhibitors.

Discovery of (S)-N-(2-amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6h)-yl)ethyl)benzamide As Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate.

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Dithiocarbamate Moiety As Novel FAK Inhibitors with Antitumor and Anti-Angiogenesis Activities.

Modification, Biological Evaluation and 3D QSAR Studies of Novel 2-(1,3-diaryl- 4,5-Dihydro-1h-pyrazol-5-yl)phenol Derivatives As Inhibitors of B-Raf Kinase.

Discovery, Optimization, and Evaluation of Quinazolinone Derivatives with Novel Linkers as Orally Efficacious Phosphoinositide-3-Kinase Delta Inhibitors for Treatment of Inflammatory Diseases

Design, synthesis, biological evaluation, in silico ADME prediction and molecular docking of pyrazole-benzamides as multitargeting protien kinase inhibitors

Design, Synthesis and Biological Evaluation of Pyrazol-Furan Carboxamide Analogues As Novel Akt Kinase Inhibitors

Design, synthesis and biological evaluation of novel benzimidazole-derived p21-activited kinase 4 (PAK4) inhibitors bearing a 4-(4-methylpiperazin-1-yl)phenyl scaffold as potential antitumor agents

Structure-based Design, Synthesis and Biological Evaluation of Diphenylmethylamine Derivatives As Novel Akt1 Inhibitors

Structure-Based Rational Design Enables Discovery of a New Selective and Potent Akt Degrader with Improved Dermatologic Safety

Design, Synthesis, and Biological Evaluation of 2‐Aminothiazole Derivatives as Novel Checkpoint Kinase 1 (CHK1) Inhibitors

Discovery of Novel Pyrrolo[2,3- d ]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors

Discovery of 2,4-Diarylaminopyrimidine Derivatives Bearing Sulfonamide Moiety As Novel FAK Inhibitors

Synthesis of Novel Sulfonamide Derivatives Containing Pyridin-3-ylmethyl 4-(Benzoyl)piperazine-1-carbodithioate Moiety As Potent PKM2 Activators.